Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
58-year-old woman with relapsed refractory multiple myeloma on bispecific therapy.
Key insights on bispecifics for relapsed/refractory multiple myeloma (R/R MM).
Key insights on bispecific antibodies for relapsed/refractory multiple myeloma.
Unmet needs and future directions for improving bispecific therapy in multiple myeloma.
Optimal Dosing Strategies and Adverse Event Management
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
58-year-old woman with relapsed refractory multiple myeloma on bispecific therapy.
Key insights on bispecifics for relapsed/refractory multiple myeloma (R/R MM).
Key insights on bispecific antibodies for relapsed/refractory multiple myeloma.
Unmet needs and future directions for improving bispecific therapy in multiple myeloma.
Optimal Dosing Strategies and Adverse Event Management
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
